Budiodarone

Drug Profile

Budiodarone

Alternative Names: ATI-2042

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator ARYx Therapeutics
  • Developer Armetheon
  • Class Benzofurans; Class III antiarrhythmics; Small molecules
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ventricular tachycardia
  • Discontinued Atrial fibrillation

Most Recent Events

  • 26 May 2016 Discontinued - Phase-II for Atrial fibrillation in Canada, European Union, USA, USA (PO) because Armetheon focussing on Ventricular tachycardia
  • 26 May 2016 Phase-II clinical trials in Ventricular tachycardia in USA (PO)
  • 26 May 2016 Armetheon acquires budiodarone from ARYx Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top